- Home
- OTAI vs BMEA Comparison
OTAI vs BMEA Comparison
Compare OTAI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTAI | BMEA |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.6M | 140.3M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OTAI | BMEA |
|---|---|---|
| Price | $10.00 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.83 |
| AVG Volume (30 Days) | 3.6K | ★ 2.0M |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $0.87 |
| 52 Week High | $10.73 | $2.99 |
Technical Indicators
Market Signals| Indicator | OTAI | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 56.35 |
| Support Level | $9.93 | $1.17 |
| Resistance Level | $10.03 | $2.00 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 8.84 | 54.91 |
Price Performance
Historical ComparisonAbout OTAI Starlink AI Acquisition Corporation Ordinary Shares
Starlink AI Acquisition Corp is a blank check company.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.